AU5205999A - Alkylamines and their precursors as specific modulators of human gamma-delta t cell function - Google Patents

Description

WO 00/00158 PCT/US99/14303 ALKYLAMINES AND THEIR PRECURSORS AS SPECIFIC MODULATORS OF HUMAN GAMMA-DELTA T CELL FUNCTION Government Support The work described herein was supported, in part, by Grant Nos. Al 01330-3 and CA/Al 5 47724-11 from the National Institutes of Heath. The government may retain certain rights in these inventions. Field Of The Invention This invention relates to methods and compositions for stimulating a y6 T cell-mediated immune response against tumors and against infectious diseases, such as bacterial and viral 10 infections. Such y8 stimulation may also be used to decrease autoimmunity or to enhance immune tolerance to allergens. The methods involve administering an alkylamine or an alkylamine precursor to a subject or to cells isolated from a subject to stimulate activation, proliferation, cytokine release, cytotoxic activity or apoptosis of Vy2VS2 T cells. Background of the Invention 15 T cells are thymus derived cells in the immune system which mediate the cellular immune response. T lymphocytes (T cells) include two subgroups: a T cells and y8 T cells. The up T cells have ap receptors that recognize antigenic peptides that are bound to the major histocompatibility complex (MHC) I or II molecules; these represent approximately 90-98% of T cells. The y8 T cells have y8 receptors; these represent 3-5% of T cells. 20 y8 T cells play an important role in the defense against bacterial and viral infections as well as in autoimmunity. y6 T cells are expanded in humans with infectious diseases such as tuberculosis, salmonellosis, brucellosis, ehlichiosis, tularemia, malaria, leishmaniasis, mononucleosis, and in HIV (early stages). These cells are expanded in the synovium of patients with rheumatoid arthritis, in the CSF and CNS plaques of patients with multiple sclerosis, and 25 in the lungs of patients with sarcoidosis. In contrast to up T cells, which recognize peptide antigens in the context of MHC molecules, the predominant subset of y 6 T cells in human peripheral blood, termed Vy2V62 T cells, recognize unprocessed nonpeptide phosphate antigens in the absence of professional antigen presenting cells (APC). Contrary to the abundant information available regarding the nature of the interaction between the up T cell 30 receptor with the MHC-bound peptide antigens, the little information regarding the nature of the interaction between the y8 T cell receptors and their ligands. The antigens responsible for expanding y 8 T cells have been most extensively studied WO 00/00158 PCT/US99/14303 from mycobacteria, where they were identified as prenyl pyrophosphates. One such natural antigen is iso-pentenylpyrophosphate, which is secreted by mycobacteria. TUBag 1 and 2 are another group of closely related antigenic molecules that have been isolated from the cytoplasm of mycobacteria. These also are pyrophosphate-containing molecules whose complete 5 structures have not been determined. Other naturally occurring but less potent antigens include 2,3 diphosphoglycerate, glycerol-3-phosphate, ribose-1-phosphate, and xylose-1-phosphate. In addition to these naturally occurring antigens, there are several alkyl and alkenyl phosphate and pyrophosphate analogs that have been synthesized and that reportedly are recognized by Vy2V62 T cells. (See, 10 e.g., U.S. 5,639,653, issued to Bloom et al., for a complete description of these phosphate- or pyrophosphate-containing compounds.) Because y8 T cells protect against a variety of bacterial and viral diseases and have been implicated in modulating autoimmunity and immune tolerance, there exists a need to selectively stimulate this subpopulation of T cells to enhance an immune response to these diseases and 15 conditions, as well as to better understand the molecular processes underlying y8 T cell mediated immune responses. In view of the foregoing, there also exists a need to develop improved drug therapies to replace or supplement the existing methods for stimulating a Vy2V62 T cell-mediated immune response and, preferably, to develop novel drugs to reduce bacterial or viral infections and autoimmune conditions at their earliest stages, and to enhance 20 immune tolerance. Summary Of The Invention The invention is based on the discovery that alkylamines, which are the major products of certain bacteria that are associated with sepsis, chorioamnionitis, preterm labor, enteritis, gingivitis and also are found in plant foods and human body fluids, cause proliferation of 25 Vy2V82 T cells in a T cell receptor (TCR)-specific manner. The alkylamine antigens are the first phosphate-free antigens described for Vy2VS2 T cells and, thus, represent a distinct chemical class of ligand for Vy2VS2 T cells. The discovery that the alkylamines stimulate y6 T cell expansion is surprising and unexpected since all previously described antigens for Vy2V82 T cells are characterized by a critical phosphate or pyrophosphate moiety. Thus, 30 contrary to expectations, the working examples provide evidence that the same Vy2VS2 T cell receptor which recognizes the previously characterized negatively charged alkylphosphate compounds can be activated by the positively charged alkylamine molecules as well. Based on WO 00/00158 - 3 - PCT/US99/14303 these discoveries, Applicant describes herein a newly discovered function for alkylamines, namely, the ability to stimulate activation and/or proliferation of Vy2VS2 T cells. Accordingly, the instant invention is directed to compositions of alkylamines and novel alkylamine precursors, as well as to methods that are based upon the discovery of this newly-discovered 5 function. The methods of the invention involve administering an alkylamine agent to a subject or to cells isolated from a subject to stimulate activation and/or proliferation of the Vy2VS2 T cells. Activation of Vy2VS2 T cells is a process that is mediated by the y8 T cell receptor. In general, activation of T cell receptors is effected by binding of the receptors to their respective 10 antigens. Although not intending the invention to be limited to any particular theory or mechanism, the evidence provided in the examples suggests that activation of the y8 T cell receptor also may be initiated by binding of the alkylamines of the invention to the y8 T cell receptor. Depending upon the intra- and extra-cellular environment, activation of the Vy2VS2 T 15 cells can initiate a number of cellular changes including, but not limited to, proliferation of Vy2V82 T cells, stimulation or inhibition of cytokine production by the Vy2VS2 T cells, stimulation or inhibition of cytotoxic activity by Vy2VS2 T cells, and stimulation of the Vy2VS2 T cells to undergo apoptosis and die. Thus, the invention also embraces methods and compositions for these particular aspects of activating Vy2V82 T cells. Each of these activities 20 has been well documented in, for example, a/p T cells, and can be assessed using standard procedures (e.g., ELISA assays to measure cytokine release, apoptosis assays). For example, following activation by antigen, CD4 T lymphocytes produce one of two distinctive cytokine profiles which has led to their classification as T helper 1 (TH1) and T helper 2 (TH 2 ) cells. The different cytokines produced by these cells lead to differences in immune function. THi cells 25 primarily secrete interferon-gamma (IFN-gamma), but also interleukin-2 (IL-2) and tumor necrosis factor-beta (TNF-beta, Lymphotoxin), and induce cellular immunity. TH2 cells primarily secrete interleukin-4 (IL-4), but also IL-5 and IL- 10, and downregulate cellular immunity while playing a major role in the induction of antibody responses mediated by plasma cells. The cytokine TNF-a can be produced during both THi and TH 2 immune responses, 30 although levels are higher in TH1 responses and this cytokine is known for cytolytic effects that contribute to the efficacy of cellular immunity. Most of the original work on THi and TH 2 lymphocyte subsets was performed with mouse helper T cell clones, however, it is now WO 00/00158 PCT/US99/14303 recognized that human CD4 T cells secrete similar cytokine profiles and can also be classified into TH1 and TH2 subsets (Powrie, F. et al., 1993, Immunol. Today 14:270; Romagnani, S. et al., 1992, Int. Arch. Allergy Immunol. 4:279; Romagnani, S. et al., 1991, Immunol. Today 8:256). Although not intending to limit the invention to any particular theory or mechanism, in view of 5 the discoveries disclosed herein, it is believed that the alkylamines of the invention are capable of stimulating cytokine production by Vy2VS2 T cells in a manner analogous to that described in the literature for ut/p T cells. Thus, the ability of the alkylamines of the invention to induce Vy2VS2 T cell activation can be determined using routine experimentation and standard procedures to measure well established cellular characteristics. 10 According to one aspect of the invention, a method for stimulating activation of Vy2VS2 T cells is provided. The method for stimulating activation involves contacting the cells with a Vy2VS2 T cell activation stimulating amount of an alkylamine agent, in vivo or ex vivo, to stimulate activation of the Vy2V82 T cells. As used herein, "contacting the cells" with the alkylamine agent means placing the cells in sufficient proximity to the alkylamine agent for 15 a time and under conditions sufficient for the alkylamine to stimulate the activation of the Vy2VS2 T cells. Activation is assessed using routine procedures. Contacting may be performed in vivo or ex vivo. According to another aspect of the invention, a method for stimulating the proliferation of Vy2VS2 T cells is provided. The method involves contacting the cells with a Vy2VS2 T cell 20 proliferation stimulating amount of an alkylamine agent, in vivo or ex vivo, to stimulate proliferation of the Vy2VS2 T cells. A proliferation stimulating amount of an alkylamine agent can be the same as an activation stimulating amount of the agent; such amounts are determined by performing routine tests to determine whether the amount has induced proliferation (e.g., by counting cell numbers) or activation (e.g., by measuring cytokine 25 production by the cells). As used herein, "contacting the cells" with the alkylamine agent means placing the cells in sufficient proximity to the alkylamine agent for a time and under conditions sufficient for the alkylamine to stimulate the proliferation of the Vy2VS2 T cells and/or to activate the y8 T cell receptor. Contacting may be performed in vivo or ex vivo. 30 As used herein, "stimulating the proliferation of Vy2V62 T cells" means increasing the number of Vy2V82 T cells by a detectable, statistically significant amount or by an amount that results in a phenotypic change in the subject or in the cell that is contacted with the alkylamine WO 00/00158 PCT/US99/14303 agent. By stimulating the proliferation of Vy2VS2 T cells, it is believed that an enhanced immune response is generated against microbes and tumor cells that express antigens recognized by the Vy2VS2 T cells. In autoimmune conditions in which Vy2VS2 T cells may limit tissue damage, thereby effectively treating the disease or condition, increased proliferation 5 of such Vy2VS2 T cells would be desirable. For ease of discussion, such diseases or conditions are collectively referred to as "diseases" or "conditions" throughout this document. Exemplary diseases that can be treated (prevent, inhibit the progression, or reduce the symptoms) by stimulating the proliferation of Vy2VS2 T cells include infectious disease, e.g., bacterial or viral infections, such as gingivitis-causing bacteria, E coli infections, listeria infections, tuberculosis, 10 salmonellosis, plasmodium infections, bacteriodes infections, porphyromonas infections, klebsiella infections, Yersinia infections, clostridium infections, brucellosis, ehlichiosis, tularemia, malaria, leishmaniasis, mononucleosis, Epstein-Barr viral infections (EBV), HIV infections, and herpes simplex virus infections. Other diseases that can be treated include allergies to food or inhaled allergens, parasitic infections, leukemia, lymphoma, leprosy, 15 malaria, rheumatoid arthritis, ulcerative colitis, anemia, systemic lupus erythematosus, Lyme disease, viral hepatitis, and Crohn's disease. Although not intending to limit the invention to a particular mechanism of action, it is believed that Vy2VS2 T cells may act by down-regulating autoreactive a/P T cells that are known to cause disease by reacting against autoantigens or allergens. Alkylamine recognition by Vy2VS2 T cells may thus result in greater down 20 regulation of a/p T cells and less tissue damage or allergic reaction. For in vivo applications, the alkylamine agent administered to a subject is an isolated alkylamine agent (an "alkylamine of formula I or II" or an "alkylamine precursor of formula II") in an amount effective to stimulate the proliferation of Vy2VS2 T cells in vivo. As used herein, a subject refers to a mammal preferably a primate and, more preferably, a human. It is 25 noted that the preferred subjects treated according to the methods set forth above are otherwise free of symptoms calling for alkylamine agent treatment, either by administration of the alkylamine or by an alkylamine precursor. Preferably, the alkylamine agent is administered to the subject in conjunction with other methods for treating the condition, such as an infectious condition (e.g., antibiotic therapy). Thus, the compositions and methods of the invention are 30 useful for replacing existing drug therapies, as well as for improving the effectiveness of existing therapies for treating conditions that are characterized by inadequate numbers or function of Vy2VS2 T cells. In general, such conditions are associated with infectious disease WO 00/00158 PCTIUS99/14303 or autoimmune conditions such as those identified herein or by assessing the number of Vy2VS2 T cells in peripheral blood mononuclear cells (PBMC) using standard procedures. For example, y8 T cells are expanded in certain autoimmune disorders (e.g., synovium of patients with rheumatoid arthritis, in the CSF and CNS plaques of patients with multiple sclerosis, and 5 in the lungs of patients with sarcoidosis). In a particularly preferred embodiment, the alkylamine agent is delivered directly to the site at which there is an infection. For example, treating bacterial- or viral-mediated gingivitis, can be accomplished by formulating the alkylamine agent into a medicament that is suitable for oral delivery and that remains in the proximity of the gingival tissue (e.g., a chewing gum, a 10 floss, a gingival tissue implant). In this manner, the compositions can be targeted to particular sites within the gums to stimulate Vy2VS2 T cell proliferation at these sites. According to yet another preferred embodiment, the alkylamine agent is delivered directed to the female reproductive tract for treating the progression of opportunistic infections. For example, the alkylamine agents of the invention can be formulated for, e.g., vaginal delivery. Optionally, the 15 alkylamine agent is delivered in combination with an anti-infective agent, such as an antibiotic or anti-viral agent for treating the infective agent. According to yet another aspect of the invention, a method for activating a y8 T cell receptor is provided. The method involves contacting the receptor with an alkylamine of formula I, as defined below, under conditions to permit alkylamine-mediated activation of the 20 receptor. As used herein, a y8 receptor is a term of art which refers to the T cell receptor which recognizes antigenic molecules, and which is present on y8 T cells. Thus, the method of the invention can be performed ex vivo (e.g., on y8 T cell receptors that are expressed on isolated cells) or in vivo. The alkylamine agents that are useful for practicing the claimed invention are 25 alkylamines or alkylamine precursors. Preferably, the alkylamine agents are in isolated form, i.e., substantially free of contamination that would preclude pharmaceutical use. No prior use for the alkylamines or alkylamine precursors of the invention for treating infectious disease, allergies, or autoimmune conditionsthat can be treated by increasing the proliferation of Vy2V62 T cells or for activating a y6 T cell receptor has been proposed. 30 As used herein an "alkylamine" refers to a compound of formula I or III. The preferred alkylamines are compounds of formula I: R-NH2 (formula I), WO 00/00158 PCTIUS99/14303 wherein R is a straight- or branched chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive. The preferred alkylamines are ethyl-, n-propyl-, -iso-propyl-, n-butyl, iso-butyl-, sec-butyl-, and iso-amylamines. R optionally contains substituted functional groups including, e.g., hydroxy, amino, and 5 carboxyl. Although a primary amine is shown in formula I, secondary or tertiary amines of formula III and alkylamine precursors of formula II which, upon hydrolysis, form primary and secondary amines also are embraced within the instant invention. There are several other amine molecules that also are found as naturally occurring bacterial products or constituents of plant foods and human body fluids which are slightly less 10 structurally related to the alkylamine antigens described above. Chief among these is putrescine (1,4-butanediamine) which is n-butylamine with an additional amine group on the fourth carbon. Putrescine is essential for mammalian cell proliferation and differentiation. It is a precursor for GABA, the major neuroinhibitory substance in the vertebrate CNS. It causes gastrointestinal mucosal cell growth in vitro and in vivo, and is a metabolic product of certain 15 bacterial species including Listeria, Clostridia, Bacteroides, Escherichia, Salmonella, Shigella, and Proteus. Since putrescine has a 4 carbon chain and differs from the antigenic molecule n butylamine by only the addition of an amine group, there is a high likelihood that it will be recognized by Vy2VS2 T cells. The higher polyamine spermidine is a product of the addition to putrescine of an n-propylamine moiety derived from the decarboxylation of S 20 adenosylmethionine. It is also important in cell proliferation and is found in bacteria. Thus, spermidine will also be tested as a potential antigen for Vy2V82 T cells. According to yet another aspect of the invention, novel alkylamine precursors are provided. As used herein, an "alkylamine precursor" refers to a compound of formula II, 0 25 || R1-C-NH-R (formula II), wherein R is a straight- or branched chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive, and wherein RI is a straight- or branched chain alkyl or alkenyl group 30 containing from one to twenty carbon atoms, inclusive. Thus, R may contain 1, 2, 3, 4, 5, or 6 carbon atoms and R1 may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. Preferably, RI contains from one to ten carbon atoms, inclusive. The R and RI groups are, independently, straight-chained or branched-chain and may be saturated or WO 00/00158 PCTIUS99/14303 unsaturated. R and R1, optionally and independently, contain substituted functional groups including, e.g., hydroxy, amino and carboxy. The preferred alkylamine precursors are theanine, N1- isopropylglutamine, N 4 -ethylasparagine, and N 5 -sec-butylglutamine. Upon cleavage, e.g., in vivo, the precursors of formula II form a mild acid (RI COON) and an alkylamine of formula I 5 or III. As used in reference to R1, an "alkyl or alkenyl group" refers to an alkyl or alkenyl chain containing from one to twenty carbon atoms, inclusive. Preferably, the alkyl or alkenyl group is present in a naturally-occurring mono-or dicarboxylic acid. Exemplary monocarboxylic acids include those in which the alkyl group is propyl, butyl, and amyl. 10 Exemplary dicarboxylic acids include the amino acids and, in particular, glutamatic acid or aspartic acid. The preferred alkylamine precursors are selected from the group consisting of theanine, N 5 - iso-propylglutamine, N4-ethylasparagine, and N 5 -sec-butylglutamine. According to another aspect of the invention, novel compositions for use in accordance with the methods of the invention are provided. Novel pharmaceutical compositions contain an 15 alkylamine of formula I or III and/or an alkylamine precursor of formula II, together with a pharmaceutically acceptable carrier. The alkylamine of formula I or III and the alkylamine precursor of formula II are as defined herein. In certain preferred embodiments, the pharmaceutical compositions are formulated as oral formulations and, more preferably, are formulated for administration to a gingival tissue (e.g., a chewing gum, tooth-paste additive, a 20 gingival tissue implant). Alternatively, the novel compositions of the invention can be formulated as a food additive or vitamin-type food supplement to reduce the likelihood of food transmitted infection and/or increase immune resistance to infectious disease or tumors by stimulating the proliferation of Vy2VS2 T cells. Additionally, the novel compositions of the invention can be formulated for delivery to the female reproductive tract, e.g., for treating the 25 progression of opportunistic infections. For example, the alkylamine agents of the invention can be formulated for vaginal delivery (e.g., jelly, tampons, and so forth). According to yet another aspect of the invention, a method for making a medicament is provided. The method involves placing an alkylamine of formula I or III and/or an alkylamine precursor of formula II in a pharmaceutically acceptable carrier. The alkylamine of formula I or 30 III and the alkylamine precursor of formula II are as defined herein. For example, these compounds may be given orally, intravenously, intrathecally, intranasally, intramuscularly, or as an inhalant, and the nature of the pharmaceutically acceptable carrier is changed appropriately WO 00/00158 PCT/US99/14303 according to the mode of administration. According to yet another aspect of the invention, a method for making a food additive or vitamin-type supplement is provided. The method involves placing an alkylamine of formula I or III and/or an alkylamine precursor of formula II in a pharmaceutically acceptable carrier and 5 formulating the composition as a food additive or vitamin-type supplement. The alkylamine of formula I or III and the alkylamine precursor of formula II are as defined herein. The invention also contemplates the use of the alkylamines of formula I or III and/or the alkylamine precursors of formula II in experimental model systems to determine the role that Vy2VS2 T cell proliferation plays in combating infectious disease, as well as to determine the 10 role that these molecules play in activating the y8 T cell receptor. Thus, the invention is also directed to novel screening assays to identify molecules (e.g., by testing combinatorial libraries) that interrupt the functional activity of the alkylamine agents of the invention. These and other aspects of the invention will be described in greater detail below. Throughout this disclosure, all technical and scientific terms have the same meaning as 15 commonly understood by one of ordinary skill in the art to which this invention pertains unless defined otherwise. Brief Description Of The Drawings Figure 1 a is a reaction pathway for the metabolism of L-theanine to ethylamine and glutamate. Figure lb is a drawing of the structures of ethyl pyrophosphate and iso-pentenyl 20 pyrophosphate. Figure 2 is a series of line and bar graphs showing the effect of ethylamine on the induction of IL-2 release from Vy2VS2 and Vy1VS1 cells. Ethylamine caused IL-2 release in a polyclonal Vy2VS2 T cell line (a), Vy2VS2 T cell clones (b), but not ap T cell clones (c) nor a Vy1V81 T cell transfectant (d, open circles). The Vy2VS2 T cells clones 12G12, DG.SPF6 25 and CP. 1.15 were derived from the PBMC of healthy donors by stimulation with a mycobacterial extract, whereas DGSF. 13 was derived from the synovial fluid of a patient with rheumatoid arthritis. The up T cell clones were isolated from the PBMC of healthy donors by limiting dilution and expanded withPHA. The Vy2V62 T cell line was made by positive selection of anti-TCRS1* cells from the PBMC of a healthy donor using magnetic beads. These 30 T cells were expanded in PHA and 1 nM IL-2 and then subjected to a negative selection procedure using monoclonal antibodies OKT4 and BMA-031 treatment followed by magnetic beads charged with goat anti-mouse Ig. The final cells were >99% Vy2VS2 TCR* by flow WO 00/00158 - 10 - PCT/US99/14303 cytometric analysis. The Vy2VS2 T cell transfectant was made by transfecting TCR- J.RT3 T3.5 cells with cDNA made from DG.SF 13, a Vy2VS2 TCR+ phosphate antigen reactive y6 T cell clone obtained by stimulation of synovial fluid mononuclear cells with a mycobacterial extract. The VylV8l T cell transfectant was obtained by transfecting TCR-J.RT3-T3.5 cells 5 with cDNA made from F7, a VylVS1 TCR+ y8 T cell clone. Stimulation of T cell clones and transfectants was performed in 96 well flat bottom plates with 1 x 105 responder cells per well in 0.2 ml 47. In some experiments, 5 x 104 mitomycin-treated or glutaraldehyde-fixed B lymphoblastoid cells (LCL) or SH-5YSY neuroblastoma cells per well were used as feeders or antigen presenting cells (APC), but these APC were not necessary to obtain IL-2 release from 10 the transfected Jurkat cells. Half log dilutions of ethylamine starting at 100 mM (a, d) or a fixed dose of 30mM (b, c), or as a positive control, the calcium ionophore, ionomycin, (at 1 mg/ml) were added in the presence of 10 ng/ml PMA as a costimulator 56. After 24 hr, supernatants were harvested, and tested at a final dilution of 1/8 for their ability to stimulate the growth of the IL-2-dependent HT-2 cell line. Proliferation assays were performed in triplicate using 5 x 10' 15 HT-2 cells per flat bottom well of a 96-well plate. After 18 hours, the cells were pulsed with 3 H thymidine (1 mCi/well), harvested at 24 hours, and counted by liquid scintillation on a Betaplate system. The standard deviation of the triplicate determination was less then 10% of the mean. Figure 3 is a bar graph showing the effect of acid hydrolyzed tea extracts or L-theanine on Vy2V62 T cells. Hydrolyzed green and black tea (a) and hydrolyzed L-theanine (b) caused 20 expansion of y8 T cells from PBMC. A concentrated green tea extract was made by mixing 15 g green tea leaves with 500 ml boiling water and steeping for 10 min. The mixture was centrifuged at 200 X g for 20 min and filtered to remove remaining large particles, yielding 400 ml of concentrated tea extract. This was lyophilized to yield 4 g solid material. Two grams of this extract, 2 g of Nestea iced tea (100% tea; Nestle, Lausanne, Switzerland), and 500 mg of 25 L-theanine (Sigma) were refluxed individually in 5N HCl for 2 hr and brought to pH 7.4 with NaOH. These substances were then tested for their ability to expand y8 T cells from PBMC. Hydrolyzed tea extracts were used at a 1:30 dilution, and hydrolyzed L-theanine was used at 10mM. Figure 4 is a bar graph showing the effect of alkylamines on Vy2VS2 T cell expansion. 30 PBMC were mixed with 400 mM concentrations of either alkylamines or EPP and after 7 days y8 T cells were quantitated by flow cytometry. The total number of cells in the cultures remained constant over the 7 day period. Data are expressed as the percentage of CD3* cells WO 00/00158 PCT/US99/14303 with y8 TCR. Significant expansion of y8 T cells occurred using alkylamine concentrations as low as 50 mM. All y8 T cells were Vy2VS2 as assessed using V chain specific antibodies. The ascites-derived monoclonal antibodies against T cell antigens used were as follows: control antibody (P3), pan y6 TCR (anti-TCRS1), V61/VS1 (dTCS1), VS2 (BB3), Vy2 (7A5), and 5 CD3 (OKT3). The specificity of these antibodies is reviewed in ". FITC-conjugated (Fab') 2 goat anti-mouse IgG was purchased from Tago, (Burlingame, CA). Ethyl pyrophosphate (EPP) was synthesized as described 23. Alkylamines were purchased from Sigma Chemical Company (St. Louis, MO). Figure 5a is a line graph showing the effect of Proteus morganii bacterial supernatants 10 and their extracts on Vy2V62 PBMC T cell expansion. Supernatants and their extracts caused expansion of Vy2V62 T cells from PBMC. Supernatant from a broth culture of Proteus morganii (circles), an extract from this supernatant enriched for amines (triangles), and uninoculated bacterial culture media (squares) were mixed with PBMC. On day 3, 0.3 nM IL-2 was added to all cultures. On day 12, cells were analyzed by flow cytometry with anti-yb TCR 15 monoclonal antibodies to enumerate y8 T cell numbers. The total number of cells in the cultures remained constant over the 12 day period. Data are expressed as the percentage of CD3+ cells with y8 TCR. Greater than 99% of y8 T cells were Vy2VS2+ T cells as assessed using V chain specific antibodies. Proteus morganii, strain 235, (National Collection of Types Cultures, London) was grown in LB broth at 37 C overnight. The culture supernatant was 20 obtained by centrifugation at 2000 g for 10 minutes. To enrich for alkylamines, 10 ml of supernatant was saturated with NaCl and brought to pH 1.5 with concentrated sulfuric acid. After centrifugation at 2000 g for 10 minutes, the supernatant was extracted thrice with 7 ml diethyl ether and the aqueous extract was brought to pH 12 with 10 N NaOH. This fraction was then extracted thrice with 7 ml chloroform followed by an extraction of the organic phase with 3 25 ml 5 N HCl. The aqueous phase was then dried in an oven at 95 C, reconstituted with 1 ml

H

2 0, brought to pH 7.4, and passed through a 0.45 micron filter. Figure 5b is a bar graph showing the effect of alkaline phosphatase treatment on the ability of bacterial supernatants to expand y8 T cells. Alkaline phosphatase treatment of supernatants from bacterial broth cultures of Porphyromonas gingivalis and Porphyromonas 30 intermedius has no effect on their ability to expand y8 T cells. Bacterial supernatants or EPP were treated with alkaline phosphatase 23 and cultured with PBMC at a dilution of 1:6 to test their ability to expand y8 T cells. As a control, alkaline phosphatase treatment reduced the WO 00/00158 - 12 - PCT/US99/14303 EPP-mediated expansion of y 8 T cells in PBMC from 9.6 to 6.1% of CD3+ cells in experiment 1, and from 26.9 to 6.0% in experiment 2. Figure 6a is a line graph showing the ability of bacterial supernatants to induce IL-2 release from T cells. Alkaline phosphatase treatment of extracts of Proteus morganii broth 5 culture supernatants had no effect on their antigenic ability. Monoethylphosphate (circles), iso butylamine (squares) or extracts of Proteus supernatants (triangles) were treated with alkaline phosphatase (open symbols), or mock-treated (closed symbols) and used as antigens to stimulate IL-2 release from the Vy2VS2 TCR transfectant DBS43. Half-log dilutions of alkylamine antigen stock solutions were added to 10' responder TCR transfectants in the presence of 10 nM 10 phorbol myristate acetate as a co-stimulator. After 24 hours, supernatants were harvested and tested at a final dilution of 1/8 for their ability to stimulate the growth of the IL-2 dependent HT-2 cell line. Alkaline phosphatase treatment was carried out as follows: 500 pl of either undiluted bacterial supernatant, or a bacterial supernatant extracted to enrich for amines (as described above) or a 10 mM solution of purified alkylamines (e.g., 10 mM iso-butylamine or 15 10 mM monoethylphosphate) were mock-treated or treated with 5 units of shrimp alkaline phosphatase (Sigma) for 2 hours at 37 C and used as antigens. Figure 6b is a line graph showing the ability of purified alkylamines to induce IL-2 release from a Vy2VS2 TCR transfectant, DBS43. DBS43 requires approximately 100-fold more alkylamine antigen concentration for a detectable IL-2 response as compared to y8 T cell 20 expansion from PBMC. There was no detectable IL-2 release from a Vy1VS1 TCR transfectant (data not shown). Figure 7 is a list of phosphate and alkylamine antigens and their corresponding structures. Figure 8 is a series of bar graphs showing the effect of APC on ethylamine recognition 25 by Vy2VS2 T cells. APC had no effect on TCR-dependent recognition of ethylamine by a Vy2VS2 TCR transfectant. SH-5YSY neuroblastoma cells (right panels) or EBV-transformed lymphoblastoid cells (data not shown) were treated with mitomycin C and added as APC to a Vy2V82 TCR transfectant and the response to ethylamine was measured by IL-2 release and compared to the IL-2 response seen without APC (left panels). Whereas APC enhanced the 30 response to ethylpyrophosphate by about 100-fold (lower panels), there was no detectable effect of APC on the response to ethylamine (upper panels). Figure 9 illustrates an exemplary synthetic reaction for forming the alkylamine WO 00/00158 - 13 - PCT/US99/14303 precursors of the invention. Figure 10 illustrates the hydrolysis of an alkylamine precursor of formula II. Detailed Description Of The Invention The invention is based on the discovery that alkylamines cause proliferation of Vy2VS2 5 T cells in a T cell receptor (TCR)-specific manner. The alkylamine antigens are the first phosphate-free antigens described for Vy2VS2 T cells and, thus, represent a distinct chemical class of ligand for Vy2VS2 T cells. The discovery that the alkylamines stimulate y8 T cell expansion is surprising and unexpected since all previously described antigens for Vy2VS2 T cells are characterized by a critical phosphate or pyrophosphate moiety. 10 As used herein, Vy2VS2 T cells refer to thymus-derived cells in the immune system which mediate cellular immune reactions and regulate immune response, and characterized by the presence of specific y8 T cell antigen receptors expressed on their cell surface. These specific y8 T cell antigen receptors (TCR) are composed of rearranged (TCR) y and (TCR) 8 chains which incorporate variable domains encoded by the germline variable (V) domain gene 15 segments Vy2 (Vy9 is alternate nomenclature) and V82, respectively. These cells may include certain T cell clones, T cell lines, T cell hybridomas, as well as naturally occurring populations of T cells arising or present in a mammal. As discussed above, depending upon the intra- and extra-cellular environment, activation of the Vy2VS2 T cells can initiate a number of cellular changes including, but not 20 limited to, proliferation of Vy2VS2 T cells, stimulation or inhibition (e.g., blocking) of cytokine production by the Vy2VS2 T cells, stimulation or inhibition of cytotoxic activity by Vy2VS2 T cells, and stimulation of the Vy2VS2 T cells to undergo apoptosis and die. Thus, the invention also embraces methods and compositions for these particular aspects of activating Vy2V62 T cells. Each of these activities has been well documented in, for example, a/p T cells, and can be 25 assessed using standard procedures (e.g., ELISA assays to measure cytokine release, apoptosis assays). For example, following activation by antigen, CD4 T lymphocytes produce one of two distinctive cytokine profiles which has led to their classification as T helper 1 (TH1) and T helper 2 (TH 2 ) cells. The different cytokines produced by these cells lead to differences in immune function, i.e., upregulation or downregulation of the immune response. 30 According to one particular aspect of the invention, a method for stimulating activation of Vy2V82 T cells is provided. The method for stimulating activation involves contacting the cells with a Vy2VS2 T cell activation stimulating amount of an alkylamine agent, in vivo or ex WO 00/00158 -14- PCT/US99/14303 vivo, to stimulate activation of the Vy2VS2 T cells. As used herein, "contacting the cells" with the alkylamine agent means placing the cells in sufficient proximity to the alkylamine agent for a time and under conditions sufficient for the alkylamine to stimulate the activation of the Vy2VS2 T cells. Activation is assessed using routine procedures. Contacting may be 5 performed in vivo or ex vivo. According to another aspect of the invention, a method for stimulating the proliferation of Vy2VS2 T cells is provided. The method involves contacting the cells with a Vy2VS2 T cell proliferation stimulating amount of an alkylamine agent, in vivo or ex vivo, to stimulate proliferation of the Vy2VS2 T cells. As used herein, a "Vy2V82 T cell proliferation 10 stimulating amount" refers to the amount effective to induce the proliferation of the Vy2VS2 T cells. Such proliferation can be detected by using standard procedures to measure the number of cells before and after treatment with the alkylamine agents. A statistically significant increase in the number of cells following treatment with the alkylamine agent is a Vy2VS2 T cell proliferation stimulating amount. Preferably, for ex vivo applications, this amount is from 15 about 0.01 mM to about 100 mM, more preferably from about 0.1 mM to about 20 mM, and most preferably from about 1 mM to about 10 mM. For in vivo applications, the preferred amounts are from about 5 mg/kg to about 100 mg/kg, more preferably from about 10 mg/kg to about 50 mg/kg, and most preferably from about 20 mg/kg to about 30 mg/kg. Contacting the Vy2VS2 T cells with the alkylamine agents of the invention can be 20 effected in vivo or ex vivo. Thus, contacting refers to exposing the Vy2VS2 T cells to the alkylamine agent under conditions and for a sufficient period of time to permit the alkylamine agent to stimulate proliferation of the Vy2VS2 T cells. Contacting may be effected by administering to a subject in need of such treatment a Vy2VS2 T cell proliferation inducing amount of the alkylamine agent. Alternatively, biological fluid (preferably containing Vy2VS2 25 T cells) can be removed from the subject, treated with the alkylamine agents of the invention, and reinfused into the subject in accordance with standard practice. Such biological fluids include, but are not limited to sera, cerebrospinal fluid, and synovial fluid. The preferred fluid is blood. In one aspect, the invention is directed to a method for treating a subject diagnosed as 30 having a condition that is associated with an antigen that is recognized by Vy2VS2 T cells. By stimulating the proliferation of Vy2VS2 T cells, it is believed that an enhanced immune response is generated against the condition. The method of treatment involves administering to WO 00/00158 - 15 - PCT/US99/14303 the subject an isolated alkylamine agent in an amount and in a manner effective to induce proliferation of Vy2VS2 T cells and/or to activate the y8 T cell receptor. The particular mode of administration will depend upon the nature of the condition and the location of the Vy2VS2 T cells that are being targeted by the alkylamine agents. Exemplary conditions that are 5 associated with an antigen that is recognized by Vy2VS2 T cells are known to those of ordinary skill in the art and include, but are not limited to, the following diseases: infectious diseases such as tuberculosis, salmonellosis, brucellosis, ehlichiosis, tularemia, malaria, leishmaniasis, mononucleosis, and in HIV. Additional conditions in which increased numbers of Vy2VS2 T cells may be desirable include autoimmune diseases such as rheumatoid arthritis, multiple 10 sclerosis, and sarcoidosis. The alkylamine agents of the invention are particularly useful for treating gingivitis that is associated with an antigen that is recognized by Vy2V82 T cells. Most studies examining the reactivity of Vy2V82 T cells to defined antigens have used peripheral blood mononuclear cells (PBMC) as a source of y8 T cells and phosphate antigens isolated from mycobacteria as 15 stimulants. Although not intending the invention to be limited to a particular theory or mechanism, we believe that y6 T cells found in other anatomic compartments such as the gingiva, in which 30% of isolated leukocytes are TCR y8+, are more likely to encounter a distinct set of pathogens. y8 T cells represent up to 60% of T cells in the female reproductive tissues such as the cervix and decidua. For example, there have been recent reports that y6 T 20 cells are activated in the gingiva of patients with chronic gingivitis, which is caused by periodontopathic mouth anaerobic bacteria such as Bacteroidesforsythus and Porphyromonas gingivalis. Such bacteria are also opportunistic pathogens in the female reproductive tract in diseases such as pelvic inflammatory disease, chorioamnionitis, postpartum endometritis, preterm labor, and postoperative infections. Our experimental results indicate that human y8 T 25 cells recognize alkylamines which are major products (produced in millimolar concentrations) of certain bacteria including the Bacteroides species. Accordingly, we believe that alkylamines can be used to treat gingivitis that is associated with an infection that is associated with an antigen that is recognized by the gingival y8 T cell, as well as infections of the female reproductive tract. For embodiments which target the gingival tissue, the preferred 30 compositions of the invention are formulated for localized delivery to the tissue (e.g., chewing gum, floss that is impregnated or otherwise coated with alkylamine agents of the invention, gingival tissue implants). Other variations on the formulation will depend upon the nature of WO 00/00158 -16- PCTIUS99/14303 the target tissue source of y8 T cells to which the therapy is directed. The alkylamine agents of the invention are administered in effective amounts. An effective amount is a dosage of the alkylamine agent sufficient to provide a medically desirable result. The effective amount will vary with the particular condition being treated, the age and 5 physical condition of the subject being treated, the severity of the condition, the duration of the treatment, the nature of the concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. For example, in connection with a diagnosed bacterial or viral infection, an effective amount is that amount which slows or inhibits the extent of the bacterial or viral infection as measured in accordance 10 with standard practice for determining bacterial or viral loads in a subject (intracorporeally or extracorporeally) or in cell culture. Likewise, an effective amount for treating gingivitis is that amount which slows, inhibits, or halts the progression of gingivitis. Thus, it will be understood that the alkylamines of the invention can be used to treat the above-noted conditions prophylactically in subjects at risk of developing the foregoing conditions. As used in the 15 claims, "inhibit" embraces all of the foregoing. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical judgment. A subject, as used herein, refers to any mammal (preferably, a primate and, more preferably, a human) that may be susceptible to a condition associated with an infection or an autoimmune condition in which an antigen that is recognized by Vy2VS2 T cells is implicated, 20 provided that the mammal is otherwise free of symptoms calling for alkylamine agent treatment. The preferred subjects are free of symptoms calling for treatment with an alkylamine agent for any reason. An alkylamine agent, as used herein, refers to an alkylamine of formula I or III and an alkylamine precursor of formula II (discussed below). Alkylamine agents are capable of 25 inducing stimulation of Vy2VS2 T cells and/or activating a y 6 T cell receptor, in vivo or ex vivo. Accordingly, the alkylamine agents of the invention are capable of reducing or preventing the proliferation of conditions that are associated with antigens that are recognized by Vy2VS2 T cells, such as the above-describedvinfectious diseases and autoimmune conditions. As used herein an "alkylamine" refers to a compound of formula I or III. The preferred 30 alkylamines are compounds of formula I: R-NH2 (formula I), wherein R is a straight- or branched chain alkyl or alkenyl group containing from one to six WO 00/00158 -17- PCT/US99/14303 carbon atoms, inclusive. Exemplary alkylamines include: monoalkylamines such as methyl, ethyl, n-propyl, n-butyl, isopropyl and alkenylamines such as allyl, crotyl, dimethylallyl, isopentenyl, geranyl, farnesyl, geranylgeranyl, 3-methyl-2-pentenyl, and 3-methyl-2-hexenyl. See also U.S. 5,639,653, issued to Bloom et al., (e.g., columns 4-7) for examples of 5 alkylgroups and substituted alkyl groups (e.g., hydroxymethyl -, p-hydroxyethyl-, 6-hydroxy propyl-, hydroxy isopropyl-) that contain six carbon atoms or less and that can be used in accordance with the instant invention. The Bloom compounds differ from those disclosed herein in that the former compounds have an absolute requirement for a phosphate or pyrophosphate moiety whereas the compounds of the instant invention have a positively 10 charged amine moiety in place of a negatively charged phosphate group. The preferred alkylamines are ethyl-, n-propyl-, -iso-propyl-, n-butyl, iso-butyl-, sec-butyl-, and iso amylamines. As used herein, an "alkylamine precursor" refers to a compound of formula II, 0 15 |1 RI -C-NH-R (formula II), wherein R is a straight- or branched chain alkyl or alkenyl group containing from one to six carbon atoms, and wherein RI is a straight- or branched chain alkyl or alkenyl group containing 20 from one to twenty carbon atoms, inclusive. Thus, R may contain 1, 2, 3, 4, 5, or 6 carbon atoms and RI may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. Preferably, RI contains from one to ten carbon atoms, inclusive. The R and RI groups are, independently, straight-chained or branched-chain and may be saturated or unsaturated. R and RI, optionally and independently, contain substituted functional groups 25 including, e.g., hydroxy, amino, carboxy and methyl groups. The preferred alkylamine precursors are theanine, N 5 - isopropylglutamine, N4-ethyl asparagine, and N 5 -sec butylglutamine. Although a primary amine is shown in formula I, it is to be understood that the invention embraces alkylamines that are secondary or tertiary amines, i.e., compounds of formula III: 30 R-NR2R3 (formula III) wherein R2 is a straight- or branched-chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive; wherein R3 is hydrogen or a straight- or branched-chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive; and wherein R2 and R3 may be the same or different from one another and from R. The invention also embraces alkylamine WO 00/00158 -18- PCT/US99/14303 precursors that can be cleaved to form the secondary or tertiary alkyl amines of formula III. As used herein in reference to R1, an "alkyl or alkenyl group" refers to an alkyl or alkenyl chain containing from one to twenty carbon atoms, inclusive. Exemplary alkyl groups include propyl, butyl, and amyl. Exemplary dicarboxylic acids include the amino acids and, in 5 particular, glutamic acid or aspartic acid. The preferred alkylamine precursors are selected from the group consisting of theanine, N 5 - iso-propylglutamine, N4-ethyl asparagine, and N 5 -sec butylglutamine. The term "isolated", as used herein, refers to a compound which is substantially free of contaminating substances which render the compound unsuitable for therapeutic applications. 10 When used therapeutically, the isolated alkylamine agents of the invention are administered in therapeutically effective amounts. In general, a therapeutically effective amount means that amount necessary to delay the onset of, inhibit the progression of, or halt altogether the particular condition being treated. Generally, a therapeutically effective amount will vary with the subject's age, condition, and sex, as well as the nature and extent of the disease in the 15 subject, all of which can be determined by one of ordinary skill in the art. The dosage may be adjusted by the individual physician or veterinarian, particularly in the event of any complication. A therapeutically effective amount typically varies from 0.01 mg/kg to about 1000 mg/kg, preferably from about 0.1 mg/kg to about 200 mg/kg, and most preferably from about 0.2 mg//kg to about 20 mg/kg, in one or more dose administrations daily, for one or more 20 days. The therapeutically effective amount of the isolated alkylamine agent is that amount effective to induce stimulation of Vy2VS2 T cells and/or activate the y8 T cell receptor as determined by, for example, standard tests known in the art. It is believed that by increasing the number of Vy2VS2 T cells, the alkylamine agents of the invention enhance the immune 25 response against diseases which are associated with agents that are recognized by the Vy2VS2 T cells. Optionally, the isolated alkylamine agents are administered to the subject in combination with other agents for treating the disease, e.g., an antibiotic for treating a bacterial infection, an antiviral agent for treating a viral infection. As used herein, antibiotic and antiviral 30 agents are terms of art that would be understood by one of skill in the art to refer to a wide spectrum of therapeutic agents which have these functional activities. See, e.g., Harrisons, Principles of Internal Medicine (McGraw Hill, Inc., New York) for a more detailed description WO 00/00158 _19 - PCT/US99/14303 of these therapeutic agents. The above-described drug therapies are well known to those of ordinary skill in the art and are administered by modes know to those of skill in the art. The drug therapies are administered in amounts which are effective to achieve the physiological goals (to prevent or 5 reduce the physiological consequences of the infection or autoimmune condition), in combination with the isolated alkylamine agents of the invention. Thus, it is contemplated that the drug therapies may be administered in amounts which are not capable of preventing or reducing the physiological consequences of the condition when the drug therapies are administered alone but which are capable of preventing or reducing the physiological 10 consequences of the condition when administered in combination with the isolated alkylamine agents of the invention. The isolated alkylamine agents may be administered alone or in combination with the above-described drug therapies as part of a pharmaceutical composition. Such a pharmaceutical composition may include the isolated alkylamine agent in combination with any standard 15 physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the isolated alkylamine agent in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration into a 20 human or other animal. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy. 25 Pharmaceutically acceptable further means a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art. 30 Compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the alkylamine agent, which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using WO 00/00158 - 20 - PCT/US99/14303 suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride 5 solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulations suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing 10 Co., Easton, PA. As noted above, variety of administration routes are available for delivering the alkylamine agents of the invention to the subject. The particular mode of delivery that is selected will depend, of course, upon the particular drug selected, the severity of the condition being treated, and the dosage required for therapeutic efficacy. The methods of the invention, 15 generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, topical, nasal, interdermal, or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intramuscular, intranasal, inhalation, or infusion. Intravenous or 20 intramuscular routes are not particularly suitable for long-term therapy and prophylaxis. There could, however, be preferred in emergency situations. Oral administration is preferred for prophylactic treatment because of the convenience to the patient as well as the dosing schedule. The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods 25 include the step of bringing the alkylamine agents into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the alkylamine agents into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product. Compositions suitable for oral administration may be presented as discrete units, such as 30 capsules, tablets, lozenges, each containing a predetermined amount of the alkylamine agents. Preferred formulations for oral administration include: implants that are constructed and arranged for implantation into gingival tissue, chewing gum containing the alkylamine agents, WO 00/00158 -21- PCT/US99/14303 floss that is impregnated with alkylamine agents, and toothpaste containing the alkylamine agents. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion. Other delivery systems can include time-release, delayed release or sustained release 5 delivery systems. Such systems can avoid repeated administrations of the alkylamine agents described above, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include the above-described polymeric systems, as well as polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, 10 polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono- di- and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using 15 conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which the alkylamine agent is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,667,014, 4,748,034 and 5,239,660 and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,832,253, and 20 3,854,480. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation. Administration of the alkylamine agents may be effected using any means known to those of skill in the art, including oral, rectoral, topical, intravenous, subcutaneous, intramuscular, or intraperitoneal routes of delivery. The alkylamine agents may be formulated 25 to achieve sustained release of the agent in vivo. Thus, for example, in one embodiment, the preferred vehicle is a biocompatible micro particle or implant that is suitable for implantation into the subject. Exemplary bioerodible implants that are useful in accordance with this method are described in PCT International application no. PCT/US/03307 (Publication No. WO 95/24929, entitled "Polymeric Gene Delivery System", claiming priority to U.S. patent 30 application serial no. 213,668, filed March 15, 1994). PCT/US/0307 describes a biocompatible, preferably biodegradable polymeric matrix. In accordance with the instant invention, the alkylamine agents are encapsulated or dispersed within the biocompatible, preferably WO 00/00158 - 22 - PCT/US99/14303 biodegradable polymeric matrix disclosed in PCT/US/03307. The polymeric matrix preferably is in the form of a micro particle such as a micro sphere (wherein the alkylamine agent(s) are dispersed throughout a solid polymeric matrix) or a microcapsule (wherein the alkylamine agent(s) are stored in the core of a polymeric shell). Other forms of the polymeric matrix for 5 containing the alkylamine agents include films, coatings (e.g., coatings onto floss), gels, and implants. The alkylamines, alone or formulated into a sustained release composition, can be used as a food or hygienic product additive. For example, in one embodiment, the alkylamines, alone or formulated as a sustained release composition, can be added to toothpaste to help control gingivitis. 10 The size and composition of the polymeric matrix device is selected to result in favorable release kinetics in the tissue into which the matrix device is implanted. The size of the polymeric matrix devise further is selected according to the method of delivery which is to be used, e.g., injection or implantation into a tissue or area of inflammation (e.g., a gingival tissue, the synovial fluid within an arthritic joint), administration of a suspension by aerosol into 15 the nasal and/or pulmonary areas. The polymeric matrix composition can be selected to have both favorable degradation rates and also to be formed of a material which is bioadhesive, to further increase the effectiveness of transfer when the devise is administered to a surface in vivo. The matrix composition also can be selected not to degrade, but rather, to release by diffusion over an extended period of time. 20 Both non-biodegradable and biodegradable polymeric matrices can be used to deliver the alkylamine agents of the invention to the subject. Biodegradable matrices are preferred. Such polymers may be natural or synthetic polymers. Synthetic polymers are preferred. The polymer is selected based on the period of time over which release is desired, generally in the order of a few hours to a year or longer. Typically, release over a period ranging from between 25 a few hours and three to twelve months is most desirable. The polymer optionally is in the form of a hydrogel that can absorb up to about 90% of its weight in water and further, optionally is cross-linked with multi-valent ions or other polymers. In general, the alkylamine agents of the invention are delivered using the bioerodible implant by way of diffusion, or more preferably, by degradation of the polymeric matrix. 30 Exemplary synthetic polymers which can be used to form the biodegradable delivery system include: polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, poly-vinyl WO 00/00158 - 23 - PCTIUS99/14303 halides, polyvinylpyrrolidone, polyglycolides, polysiloxanes, polyurethanes and co-polymers thereof, alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, polymers of acrylic and methacrylic esters, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxy-propyl methyl cellulose, hydroxybutyl methyl cellulose, 5 cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxylethyl cellulose, cellulose triacetate, cellulose sulphate sodium salt, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), 10 poly(octadecyl acrylate), polyethylene, polypropylene, poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), poly(vinyl alcohols), polyvinyl acetate, poly vinyl chloride, polystyrene and polyvinylpyrrolidone. Examples of non-biodegradable polymers include ethylene vinyl acetate, poly(meth)acrylic acid, polyamides, copolymers and mixtures thereof. 15 Examples of biodegradable polymers include synthetic polymers such as polymers of lactic acid and glycolic acid, polyanhydrides, poly(ortho)esters, polyurethanes, poly(butic acid), poly(valeric acid), and poly(lactide-cocaprolactone), and natural polymers such as alginate and other polysaccharides including dextran and cellulose, collagen, chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, 20 oxidations, and other modifications routinely made by those skilled in the art), albumin and other hydrophilic proteins, zein and other prolamines and hydrophobic proteins, copolymers and mixtures thereof. In general, these materials degrade either by enzymatic hydrolysis or exposure to water in vivo, by surface or bulk erosion. Bioadhesive polymers of particular interest include bioerodible hydrogels described by 25 H.S. Sawhney, C.P. Pathak and J.A. Hubell in Macromolecules, 1993, 26, 581-587, the teachings of which are incorporated herein, polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl 30 acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate). Thus, the invention provides a composition of the above-described alkylamine agents for use as a medicament, methods for preparing the medicament and methods for the sustained release of the WO 00/00158 - 24 - PCT/US99/14303 medicament in vivo. Use of a long-term sustained release implant may be particularly suitable for treatment of chronic conditions, e.g., chronic gingivitis. Long-term release, are used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredient for 5 at least 30 days, and preferably 60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above. The isolated alkylamine agents may be administered alone or in combination with the above-described drug therapies by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, 10 intramuscular, intra-cavity, subcutaneous, or transdermal. When using the isolated alkylamine agents of the invention, direct administration to the affected site is preferred. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl 15 oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, 20 for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like. In general, the alkylamine agents can be administered to the subject (any mammalian recipient) using the same modes of administration that currently are used for the administration of low molecular weight organic molecules. Another aspect of the invention includes a screening assay method for determining 25 whether a putative therapeutic agent modulates (upregulates or downregulates) alkylamine induced stimulation of Vy2V62 T cell proliferation and/or alkylamine-mediated activation of the y 6 T cell receptor, i.e., the method is useful for identifying alkylamine agonists that can be used in place of an alkylamine agent of the invention for stimulating Vy2V82 T cell proliferation and/or activation of the y8 T cell receptor. According to one embodiment of the 30 invention, the method involves contacting a putative alkylamine agonist (e.g., contained in a combinatorial library) with Vy2VS2 T cells under conditions to stimulate Vy2V82 T cell proliferation if an alkylamine agonist was present and determining whether the putative WO 00/00158 -25- PCT/US99/14303 alkylamine agonist stimulates Vy2VS2 T cell proliferation. Alternatively, antagonists of alkylamine activity can be identified by stimulating Vy2VS2 T cells using an alkylamine agent of the invention in the presence and absence of a putative alkylamine agent antagonist and determining whether the putative alkylamine antagonists reduces the extent of Vy2VS2 T cell 5 proliferation. In another embodiment, the screening tests are employed which measure activation of the y8 T cell receptor (instead of Vy2V82 T cell proliferation) to identify alkylamine agent agonists and/or alkylamine agent antagonists. The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention 10 and are not to be construed to limit the scope of the invention. It is also to be understood that the referenced figures are illustrative only and are not essential to the enablement of the claimed invention. Examples Example 1. Human y8 T Cells Recognize Alkylamines 15 A study in our laboratory of naturally occurring compounds potentially capable of stimulating or suppressing y8 T cell cytokine secretion showed that ethylamine was capable of inducing IL-2 release from y6 T cells. Ethylamine, a byproduct of L-theanine (Figure la) hydrolysis found in the urine of tea drinkers 22, differs from the known synthetic y8 T cell antigen ethyl pyrophosphate (EPP) 23 in that the amine group of ethylamine replaces the 20 pyrophosphate group of EPP (Figure 1 b). To further explore the reactivity of ethylamine with Vy2VS2 T cells, we measured the IL-2 release of a polyclonal y 6 T cell line coexpressing y8 variable region T cell receptor (TCR) chains (Figure 2a), four T cell clones coexpressing Vy2VS2 (Figure 2b), five up T cell clones (Figure 2c), one Vy IV81 T cell transfectant (Figure 2d, open circles) and one Vy2VS2 T cell transfectant (Figure 2d, closed circles) in response to 25 ethylamine. The Vy2VS2 T cell line, the Vy2VS2 transfectant and all four Vy2VS2 T cell clones, but neither the Vy IV81 transfectant nor the ap T cell clones, responded to ethylamine in a dose dependent manner. The Vy2VS2 T cell line (Figure 2a) and the Vy2VS2 T cell clones (Figure 2b) respectively showed on average a 4-fold and a 5-fold greater response to ethylamine as compared to media. The Vy2VS2 transfectant (Figure 2d) responded to ethylamine in a 30 manner comparable to the Vy2VS2 T cell line (Figure 2a). In contrast, there was no significant difference in the amount of IL-2 released in response to ethylamine by the 5 ap T cell clones when compared to media (Figure 2c), or by the Vy IV81 TCR transfectant (Figure 2d).

WO 00/00158 - 26 - PCTIUS99/14303 These data were unexpected since only phosphate containing antigens have been shown to stimulate Vy2V82 T cells 23-21. As expected, EPP stimulated IL-2 release from the Vy2V82 T cell line and all four Vy2V82 T cell clones. Alkaline phosphatase treatment of EPP prior to culture with the PBMC abrogated its y8 T cell reactivity, whereas this treatment had no effect 5 of the reactivity of ethylamine (data not shown). Tea beverage typically has a 2-10 mM concentration of L-theanine, an amino acid unique to all varieties of tea (Camellia sinesis) 28-30. To determine if tea beverage could cause expansion of y8 T cells in vitro, we mixed unfractionated PBMC isolated from healthy donors with green or black tea purchased commercially from a local food store and brewed according to 10 instructions. Neither green nor black teas expanded the number of y8 T cells (data not shown). However, green and black teas that were acid hydrolyzed by reflux in 5 N HCl to liberate ethylamine from L-theanine 22 caused a three- to five-fold expansion of y8 T cells (Figure 3a). Purified L-theanine failed to cause y8 T cell expansion, but acid hydrolyzed L-theanine caused a fifteen-fold expansion of y8 T cells from PBMC (Figure 3b). L-theanine hydrolysis in vivo 15 most likely occurs by acid hydrolysis in the gut and by the enzymatic action of tissue amidases in the liver 22. Our results here suggest that antigen presenting cells (APC) in the peripheral blood cannot hydrolyze L-theanine, since only acid hydrolyzed tea or purified L-theanine preparations stimulated y6 T cells. To verify that ethylamine was released by acid hydrolysis from the L-theanine in tea or from purified L-theanine, GC-mass spectrometry analysis was 20 performed on acid hydrolyzed or unhydrolyzed tea extract or L-theanine. Ethylamine was not detected in unhydrolyzed samples. In contrast, 7.2 mM ethylamine was detected in the biologically active acid hydrolyzed tea sample that was used to stimulate y6 cells. GC-mass spectrometry analysis of a purified acid hydrolyzed 1 mM L-theanine sample revealed the presence of a roughly equimolar amount (1.1 mM) of ethylamine. Taken together, these results 25 show that ethylamine resulting from hydrolysis of L-theanine found in tea is capable of expanding y8 T cells. To examine the reactivity of human y8 T cells with other naturally occurring alkylamines, peripheral blood mononuclear cells (PBMC) from healthy donors were cultured into 400 mM concentrations of either EPP or various alkylamines. After 7 to 13 days of culture, 30 we performed cell counts and flow cytometric analysis with TCR specific monoclonal antibodies. The alkylamines ethyl-, n-propyl-, n-butyl-, iso-propyl-, iso-butyl-, sec-butyl-, tert-butyl, and iso-amylamine expanded y8 T cells 2- to 15-fold compared to media alone or to WO 00/00158 - 27 - PCT/US99/14303 tetanus toxoid, which did not expand y8 T cells (Fig 4). Methyl- and n-amylamines as well as the polyamines, putrescine and spermidine, failed to expand y8 T cells from PBMC of several donors (data not shown). ap T cells were not expanded, and flow cytometry using Vy and VS-specific monoclonal antibodies revealed that all the expanded y8 T cells expressed Vy2 and 5 V62 gene segments. Such Vy2VS2 TCR classes have no homologues in nonprimates. The 31 32 alkylamines here shown to be capable of expanding y8 T cells are found in apples ", wine tea (in precursor form as L-theanine) 22, as secreted products of bacteria 31-35, human urine 36-38, breast milk, amniotic fluid 31, and in vaginal secretions from healthy women.

4 Thus, alkylamine antigens may be derived from either plant foodstuffs or from bacteria and are 10 routinely found in human body fluids. Antigenic alkylamines reportedly are found in vivo in humans in concentrations of up to 10 mM, well above the 400 ptM concentrations that elicited the y6 T cell expansions from PBMC in vitro (Figure 4). y6 T cell expansions in man have been strikingly correlated with certain microbial infections although such reactivity has been linked to alkyl phosphate antigens 7 41. Bacteroides 15 fragilis and Clostridium perfringens also produce and secrete millimolar concentrations of alkylamines and polyamines such as methylamine, dimethylamine, n-propylamine, pyrrolidine, piperidine, n-butylamine, and putrescine 4. Proteus, Salmonella, Shigella and Escherichia coli produce amines such as cadaverine, b-phenylethylamine, putrescine, iso-amylamine, 2-methylbutylamine, and iso-butylamine 3. Listeria monocytogenes produces n-butylamine and 20 putrescine during fermentation 33. Escherichia coli, Salmonella species, Listeria monocytogenes and Yersinia enterocolitica are known to cause expansion of Vy2VS2 T cells in vitro 12,42,43 and patients with Salmonellosis and Listeriosis have increased numbers of peripheral blood Vy2VS2 T cells 1. Moreover, abnormally high numbers of activated Vy2VS2 T cells are found in patients with periodontal diseases such as gingivitis 44, which is associated with 25 Bacteroides or Porphyromonas species 45. The parasite Trichinella pseudospiralis, which causes regressive and regenerative changes in muscle tissue produces large amounts of n-butylamine. Infusion of n-butylamine into mouse muscle induces microscopic pathologic changes identical to those in the muscle tissue of Trichinella pseudospiralis infected mice. Inflammatory changes are not seen, and this may be because mice lack y8 T cells that are able to recognize alkylamine 30 antigens 46 . Thus, alkylamine antigens produced in large quantities by pathogenic organisms are capable of expanding Vy2VS2 T cells in vitro, and they may have in vivo effects such as tissue destruction and expansion of Vy2VS2 T cells during certain microbial infections.

WO 00/00158 - 28 - PCT/US99/14303 To identify potential microbial sources of alkylamine antigens, fresh supernatants from bacterial broth cultures and supernatant extracts enriched for alkylamines were prepared from Proteus morganii, an important cause of urinary tract infections and urosepsis and from the anaerobic periodontopathic bacteria, Porphyromonas intermedius or Porphyromonas gingivalis, 5 (formerly genus Bacteroides). These supernatants were mock-treated or treated with alkaline phosphatase to destroy any alkyl phosphate activity that might be present and then added to cultures of PBMC from healthy donors. Cultures were maintained for 12 days and subsequently analyzed by cell counting and flow cytometry (Figure 5). Crude bacterial supernatant (circles) and alkylamine-enriched extract (triangles) from Proteus morganii induced 10 in a dose-dependent manner a 3-fold and a 7-fold increase, respectively, in Vy2VS2 T cell numbers, whereas the bacteriological media alone (squares) had no effect (Figure 5a). Quantitative headspace GC-mass spectrometry analysis revealed that the crude bacterial supernatant contained 3.4 mM iso-butylamine and 3.9 mM iso-amylamine, the alkylamine enriched extract of the bacterial supernatant contained 4.1 mM iso-butylamine and 8.4 mM iso 15 amylamine, and the uninoculated culture media had no detectable alkylamines (data not shown). Whereas alkaline phosphatase treatment totally abrogated the ability of the alkyl phosphate EPP to expand y8 T cells (data not shown), alkaline phosphatase treated or mock treated crude bacterial supernatants from Porphyromonas intermedius and Porphyromonas gingivalis both caused up to a 2-fold expansion of y8 T cells (Figure 5b). This result is consistent with the idea 20 that alkylamines found in bacterial supernatants expanded y8 T cells. To determine whether reactivity to alkylamines was TCR-dependent, we tested TCR transfectants for their ability to release IL-2 in response to bacterial supernatants (Figure 6a) and a panel of alkylamines (Figure 6b). DBS43 was made by cotransfecting cDNA encoding the Vy2 and VS2 TCR chains from the EPP reactive clone DGSF. 13 into a TCR deficient mutant of 25 Jurkat T cells. For comparison, another transfectant, 27/3.62 containing cDNA from the T cell clone F7 encoding a Vy1VS1 chain pair which lacks reactivity to EPP " was also used. An extract of Proteus supernatant enriched for alkylamines (triangles), a solution of pure iso butylamine (squares), and a solution of monoethylphosphate (circles) (i.e., as an example of a phosphate antigen) were either mock-treated (closed symbols) or alkaline phosphatase treated 30 (open symbols) (Figure 6a). Alkaline phosphatase treatment of monoethylphosphate reduced by 7-fold its ability to induce IL-2 release from the Vy2VS2 TCR transfectant (Figure 6a), but not the Vy IV81 TCR transfectant (data not shown), thus totally abrogating antigenic activity. In WO 00/00158 -29- PCT/US99/14303 contrast, this treatment failed to significantly reduce the antigenic activity of the Proteus extract or pure iso-butylamine, emphasizing that alkylamines, and not phosphate antigens, were responsible for this activity (Figure 6a). The Vy2VS2 TCR transfectant DBS43 also released significant levels of IL-2 in response to a series of other alkylamines tested (Figure 6b) whereas 5 the Vy IV81 TCR transfectant did not (data not shown). These data show also that iso-butyl and sec-butylamines were the most potent antigens on a molar basis for this particular transfected TCR, n-propyl-, iso-propyl-, n-butyl-, and iso-amylamines had intermediate potency, and ethylamine was the least potent antigen. Antigen titrations using a panel of Vy2VS2 T cell clones will reveal whether the rank order of potency seen for these antigens' 10 reactivity with the DBS43 transfectant holds for all Vy2VS2 T cell clones, or if there exist T cell clones specific for only one alkylamine. These results together with the expansion of only certain y8 T cells from PBMC, indicate that reactivity to alkylamines is critically dependent on the expression of a Vy2V82 TCR. To determine the in vivo effect of alkylamines antigens on T cells, we administered 15 intravenously 50 mg/kg iso-butylamine to each of 2 rhesus monkeys 3 times in a one week period, without co-administration of IL-2. At to (i.e., before any infusions), blood y8 T cells could be expanded up to 30-fold in vitro in response to iso-butylamine and IL-2. However, blood y 8 T cells harvested after one week of injections were unable to respond in vitro to iso butylamine and IL-2. These results show that in vivo infusions of iso-butylamine can influence 20 the in vitro reactivity of monkey y8 T cells. Infusion of pure antigens without cytokines such as IL-2 can lead to T cell unresponsiveness (i.e., anergy). To test the hypothesis that infusion of IL-2 and iso-butylamine together can cause in vivo expansion of blood y6 T cells, monkeys are intravenously administered iso-butylamine with IL-2 for 3 times during a one-week period, with measurements of T cell expansion in vitro prior to and following the administration schedule. It 25 is expected that co-administration of iso-butylamine and IL-2 will lead to in vivo expansion of blood y6 T cells rather than anergy. These results show that the same Vy2VS2 TCR can recognize a positively charged molecule (e.g., ethylamine) as well as the previously characterized negatively charged molecules such as EPP and isopentenyl pyrophosphate (IPP) . 2. This suggests that the TCR 30 might bind these two different molecules in different locations on the TCR. This is easily possible, given the small sizes of these antigens. Alternatively, the TCR may recognize the alkyl chain of either alkyl phosphates or alkyl amines at one TCR site. Distinct TCR residues WO 00/00158 - 30 - PCTIUS99/14303 adjacent to such a site may be able to provide stabilization of the TCR-antigen complex by accommodating either positive or negative charges. The functional parts of the alkyl phosphate, EPP, are the hydrophobic alkyl chain and the negatively charged phosphate moiety. Data from the present report show that substitution of the phosphate by an amine is permitted. This 5 suggests that the nature of the charge on the molecule is less important than the presence of the alkyl group. Previous data showed that alkyl groups of 1-4 carbons are necessary for straight chain alkyl phosphate reactivity and that substitutions with phenyl rings are not permitted 2. This suggests that the TCR specificity may be directed more at the hydrophobic alkyl chain than at the charged part of the EPP or ethylamine molecule. The TCR dependent reactivity of either 10 negatively charged alkyl phosphates or positively charged alkylamine antigens must therefore be accounted for in any molecular model of Vy2V82 TCR interaction with antigen. These results also show that alkylamines recognized by y8 T cells are characterized by a straight or branched alkyl chain of two to five carbons with a single primary amine group as the only substituent (Figure 7). Conversely, alkylamines with one carbon (e.g., methylamine) or 15 more than five carbons, or any substituent in addition to the primary amino group were not antigenic (Figure 7). These structural constraints on alkylamine antigens are reminiscent of those of alkyl phosphates and prenyl pyrophosphates. Alkylamines recognized by y8 T cells and having antigenic activity can be identified using in vitro screening assays as described herein. In this way, a few compounds lacking such activity have been identified. For instance, 20 the five carbon iso-amyl phosphate is not recognized, while iso-amylamine is recognized. As another example, methylamine is not antigenic, while methylphosphate is antigenic. In summary, straight or branched chain alkyl phosphates of one to four or five carbons and primary alkylamines of two to five carbons were antigenic for Vy2VS2 T cells (Figure 7). To assess the importance of APC in the T cell-mediated response to alkylamines, we 25 compared the reactivities of several alkylamines and EPP in the presence or absence of glutaraldehyde fixed SH-5YSY neuroblastoma cells as APC in IL-2 release assays. Neither the potency nor the magnitude of the response to ethylamine (Figure 8, upper panel) or several other antigenic alkylamines (data not shown) was affected by the addition of SH-5YSY APC. As expected, EPP also showed a significant reactivity in the absence of APC although reactivity 30 was increased both in magnitude (about 4-fold) and in potency (about 100-fold) by the addition of APC (Figure 8, lower panel). The use of another APC, EBV-transformed B lymphoblastoid cells, increased EPP potency by 10-fold 23 but again had no effect on the response to ethylamine WO 00/00158 PCT/US99/14303 (data not shown). This suggests that the TCR-dependent recognition of ethylamine and EPP each have different requirements for antigen presentation or costimulation. These data show that APC have no effect on TCR dependent recognition and argue for direct recognition of alkylamine antigens, similar to that seen in immunoglobulin (Ig)-hapten interactions. Several 5 lines of evidence suggest that some y6 T cells recognize antigen in a way that is more like that of an immunoglobulin than like that of an cp TCR. In the mouse, y6 T cells directly recognize the MHC class II molecule I-Ek, and the nonclassical MHC molecules T10 and T22, without peptide dependence. Site directed mutagenesis of the I-Ek MHC molecule showed that y8 T cells recognized MHC residues outside the peptide binding groove 48-49. Moreover, y8 T cells 10 recognize native HSV glycoprotein I even when bound to plastic without professional APC 5,.51 Analysis of CDR3 length distributions of TCRS chains indicates that they are more similar to those of IgH than to TCRa and TCRP chains 52, and finally, atomic structure analysis of human VS3 indicates that this TCR models more closely on Ig V domains than on TCRa or P V domains" . Crystallographic studies have shown that immunoglobulins recognize small 15 phosphate-containing molecules such as phosphorylcholine in a way that is highly dependent on both the heavy and light chain CDR3 regions 1. Thus, the Vy2VS2 TCR-alkylamine complex may be very similar to an Ig-hapten complex. However, preliminary evidence in our laboratory suggests that cell to cell contact may be necessary for IL-2 release by y6 T cells in response to alkylamines. 20 Detailed knowledge of the antigenic structures recognized by ap T cells has deepened our understanding of their role in immunity. One key to understanding the role of y8 T cells in immunity is to identify the antigens they recognize. The alkylamines identified herein as antigens point to recognition of bacteria in host defense, and to the potential in plant foods such as tea, apples, and wine for enhancing immunity, and also for a potential role for y8 T cells in 25 autoimmunity and enhancing immune tolerance to allergens. Further study will be needed to determine the precise nature of interaction between the Vy2V82 TCR and their antigens. However, this study clearly shows that alkylamines are a large class of newly identified Vy2VS2 T cell antigens with chemical and biological properties distinct from phosphate antigens. Found in plant foods, human body fluids, and bacteria, alkylamines are likely to play a 30 major role in Vy2VS2 T cell activity in vivo. Vy2VS2 T cells may be considered part of the adaptive immune system in that they have a memory phenotype 8 , they express junctionally diverse TCR 9 that require gene WO 00/00158 -32- PCTIUS99/14303 rearrangement for their cell surface expression 60 , and their ability to undergo either anergy or expansion depending on the availability of costimulation, 62 . On the other hand, Vy2VS2 T cells also may be considered part of the innate immune response since their frequently paired TCR variable region genes Vy2 and VS2 reflect limited germ line diversity. This V gene 5 pairing enables each Vy2VS2 TCR to immediately recognize families of unprocessed antigens with conserved molecular patterns such as the alkylamines and alkyl phosphates. This TCR dependent recognition of the conserved one- to five-carbon straight and branched-chain alkyl groups found in antigenic alkylamines and alkyl phosphates that are products of multiple pathogens is reminiscent of the CD 14-mediated pattern recognition of pathogen-associated 10 molecular patterns such as the repeating sugar residues found in various bacterial lipopolysaccharides 63 - 64. This pattern of recognition by the Vy2VS2 TCR allows the expansion of memory y8 T cells to large numbers in normal adults (mean 4.5% of CD3+ T cells) and to 2 to 10-fold higher levels (8-60% of CD3* T cells) during a host of microbial infections. These large numbers of memory T cells capable of responding to alkylamine antigens produced by 15 microbes thus may bridge the gap between innate and adaptive immune responses. Example 2. Alkylamine Precursor Reactions The alkylamine agents of the invention are alkylamines of formula I or III or alkylamine precursors of formula II, as described above. Precursors of alkylamines of the type in formula I 20 may be found in nature as naturally occurring compounds or may be chemically synthesized. Examples of naturally occurring precursors include the N-substituted primary amides N ethylglutamine (L-theanine) in Camellia sinesis, N 4 -ethylasparagine in Tulipa gesneriana, and

N

5 -iso-propylglutamine in Lunaria annua. Figure 9a illustrates an exemplary synthetic reaction for forming the alkylamine 25 precursors of the invention. The synthesis reaction is based upon that described by Y. Sakato, et al., in Nippon Nugei Kagadu Kaishi 23:262-271 (1949). (See, also, Morrison & Boyd, 3rd ed, Section 18 for exemplary reactions for forming and hydrolyzing an amide compound.) Exemplary RI groups in the acid structure include but are not limited to ethyl, n-propyl, iso propyl, n-butyl, iso-butyl, tert-butyl and sec-butyl. Figure 10b illustrates an exemplary reaction 30 in which an acid (e.g., L-glutamic acid) is allowed to react with an amine (e.g., ethylamine) to form an ester (e.g., L-glutamic acid y-ethyl ester) which is derivatized to form a derivatized ester. Thereafter, the derivatized ester is allowed to form the alkylamine precursor (amide).

WO 00/00158 - 33 - PCT/US99/14303 Figure 10 illustrates the hydrolysis of an alkylamine precursor of formula II. Hydrolysis can be effected in the presence either of acid or base, or by enzymatic cleavage of the amide bond (e.g., by an amidase) to yield an alkylamine of formula I or III and a mild carboxylic acid. For example, hydrolysis of N-ethylglutamine (L-theanine) yields ethylamine plus glutamic 5 acid. Naturally occurring alkylamine precursors include N-ethylglutamine (L-theanine), as found in Camellia sinesis i.e., tea; N 5 -iso-propylglutamine, as found in Lunaria annua i.e., an ornamental plant; and N5 ethylasparagine, as found in Tulipe gesneriana i.e., tulip, Echallium elaterium, i.e., squirting cucumber and Bryonia dioica. 10 References 1. Sciammas, R., Kokukula, Q., Tang, R.L., Hendricks, R.L. & Bluestone, J.A. J. Exp. Med. 185, 1969-1975 (1997). 2. Tsuji, M., et al. Int. Immunol. 8, 359-66 (1996). 3. Tsuji, M., et al. Proc. Natl. Acad Sci. USA 91, 345-9 (1994). 15 4. Hiromatsu, K., et al. J Exp. Med. 175, 49-56 (1992). 5. Peterman, G.M., Spencer, C., Sperling, A.I. & Bluestone, J.A. J. Immunol. 151, 6546-58 (1993). 6. Mengel, J., et al. Immunology Letters 48, 97-102 (1995). 7. McMenamin, C., Pimm, C., McKersey, M. & Holt, P.G. Science 265, 1869-71 (1994). 20 8. Ke, Y., Pearce, K., Lake, J.P., Ziegler, H.K. & Kapp, J.A. J. Immunol. 158, 3610-8 (1997). 9. Harrison, L.C., Dempsey-Collier, M., Kramer, D.R. & Takahashi, K. J. Exp. Med. 184, 2167-74 (1996). 10. Balbi, B., et al. Am. Rev. Respir. Dis. 148, 1685-90 (1993). 25 11. Ueta, C., et al. Infection & Immunity 62, 5434-41 (1994). 12. Hara, T., et al. J. Clin. Invest. 90, 204-10 (1992). 13. Sumida, T., et al. Infect. Immun. 60, 2554-8 (1992). 14. Bertotto, A., et al. Eur. J. Immunol. 23, 1177-80 (1993). 15. Munk, M.E., Gatrill, A.J. & Kaufmann, S.H.E. J Immunol. 145, 2434-9 (1990). 30 16. Caldwell, C.W., et al. American Journal of Clinical Pathology 105, 640-6 (1996). 17. Raziuddin, S., Telmasani, A.W., El-Awad, M.E., Al-Amari, 0. & Al-Janadi, M. Eur. J. Immunol. 22, 1143-8 (1992).

WO 00/00158 PCTIUS99/14303 - 34 18. Perera, M.K., Carter, R., Goonewardene, R. & Mendis, K.N. J. Exp. Med 179, 311-5 (1994). 19. Scalise, F., et al. Immunol. 76, 668-70 (1992). 20. De Maria, A., et al. J. Infect. Dis. 165, 917-9. (1992). 5 21. De Paoli, P., et al. J. Inf Dis. 161, 1013-1016 (1990). 22. Asatoor, A.M. Nature (Lond) 210, 1358-60 (1966). 23. Tanaka, Y., et al. Proc. Natl. Acad. Sci. USA 91, 8175-79 (1994). 24. Davodeau, F., et al. Eur. J. Immunol. 23, 804-8 (1993). 25. Birk, M.R., Mori, L. & De Libero, G. Eur. J. Immunol. 25, 2052-8 (1995). 10 26. Schoel, B., Sprenger, S. & Kaufmann, S.H.E. Eur. J. Immunol. 24, 1886-92 (1994). 27. Tanaka, Y., et al. Nature (Lond.) 375, 155-8 (1995). 28. Sakato, Y. Nippon Nogei Kagadu Kaishi 23, 262-271 (1949). 29. Cartwright, R., Roberts, E. & Wood, D. J. Sci. Food Agric. 5, 597-599 (1954). 30. Graham, H.N. Preventive Medicine 21, 334-50 (1992). 15 31. Hartmann, T. Experientia 23, 680-1 (1967). 32. Ibe, A., et al. Journal - Association of Official Analytical Chemists 74, 695-8 (1991). 33. Daneshvar, M.I., Brooks, J.B., Malcolm, G.B. & Pine, L. Canadian Journal of Microbiology 35, 786-93 (1989). 34. Allison, C. & Macfarlane, G.T. Applied & Environmental Microbiology 55, 2894-8 20 (1989). 35. Ghenghesh, K.S. & Drucker, D.B. Brazilian Journal ofMedical & Biological Research 22, 653-65 (1989). 36. Kataoka, H., Ohrui, S., Miyamoto, Y. & Makita, M. Biomedical Chromatography 6, 251-4 (1992). 25 37. Large, P.J., Eady, R.R. & Murden, D.J. Anal. Biochem. 32, 402-7 (1969). 38. Perry, T.L., Shaw, N.F., Walker, D. & Redlich, D. Pediatrics 30, 576-584. (1962). 39. Lichtenberger, L.M., Gardner, J.W., Barreto, J.C. & Morriss, F.H., Jr. Journal of Pediatric Gastroenterology & Nutrition 13, 342-6 (1991). 40. Jones, B.M., Al-Fattani, M. & Gooch, H. International Journal of STD & AIDS 5, 52-55 30 (1994). 41. Constant, P., et al. Science 264, 267-70 (1994). 42. Munk, M.E., Elser, C. & Kaufmann, S.H.E. Immunol. 87, 230-5 (1996).

WO 00/00158 - 35- PCT/US99/14303 43. Abo, T., et al. Int. Immunol. 2, 775-85 (1990). 44. Lundqvist, C. & Hammarstrom, M.L. Immunol. 79, 38-45 (1993). 45. Tanner, A. & Stillman, N. Clinical Infectious Diseases 4, S304-9 (1993). 46. Zenka, J., Hulinska, D. & Jegorov, A. Folia Parasitol 36, 177-83 (1989). 5 47. Bukowski, J.F., et al. J. Immunol. 154, 998-1006 (1995). 48. Schild, H., et al. Cell 76, 29-37 (1994). 49. Chien, Y.H., Jores, R. & Crowley, M.P. Annu. Rev. Immunol. 14, 511-32 (1996). 50. Johnson, R.M., et al. J. Immunol. 148, 983-8 (1992). 51. Sciammas, R., et al. J. Immunol. 152, 5392-7 (1994). 10 52. Rock, E.P., Sibbald, P.R., Davis, M.M. & Chien, Y. J. Exp. Med. 179, 323-8 (1994). 53. Padlan, E.A., Davies, D.R., Rudikoff, S. & Potter, M. Immunochemistry 13, 945-9 (1976). 54. Lebedava, M.I., et al. Protein Science 5, 2638-2642 (1996). 55. Li, H., et al. Nature (Lond.) 391, 502-506 (1998). 15 56. Saito, T., Weiss, A., Miller, J., Norcross, M.A. & Germain, R.N. Nature (Lond.) 325, 125-30 (1987). 57. Porcelli, S., Brenner, M.B. & Band, H. Immunol. Rev. 120, 137-83 (1991). 58. Parker, C.M., et al., J. Exp. Med. 171, 1597-1612 (1990). 59. Panchamoorthy, G., et al., J. Immunol. 147, 3 360-3369 (1991). 20 60. Band, H., et al., Science 238, 682-684 (1987). 61. Hara, T., et al., PNAS 93, 5136-5140 (1996). 62. Pawelec, G., et al., Cell. Immunol. 162, 8-15 (1995). 63. Medzhitov, R., et al., Cell 91 295-298 (1997). 64. Medzhitov, R., et al., Curr. Opin. Immunol. 9 4-9 (1997). 25 All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference. It should be understood that the preceding is merely a detailed description of certain preferred embodiments. It therefore should be apparent to those skilled in the art that various 30 modifications and equivalents can be made without departing from the spirit and scope of the invention. It is intended to encompass all such modifications within the scope of the appended claims.

Claims (99)

1. A method for stimulating the proliferation of Vy2VS2 T cells comprising: contacting the cells with a Vy2VS2 T cell proliferation stimulating amount of an alkylamine agent selected from the group consisting of an alkylamine of formula I: 5 R-NH2 (formula I), an alkylamine of formula III: R-NR2R3 (formula III) and an alkylamine precursor of formula II, 0 10 1| R1-C-NH-R (formula II), wherein R is a straight- or branched chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive, 15 wherein RI is a straight- or branched chain alkyl or alkenyl group containing from one to twenty carbon atoms, inclusive, wherein R2 is a straight- or branched-chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive, that may be the same or different from R, and wherein R3 is hydrogen or a straight- or branched-chain alkyl or alkenyl group 20 containing from one to six carbon atoms, inclusive, that may be the same or different from R or R2.

2. The method of claim 1, wherein stimulating the proliferation comprises increasing the number of Vy2VS2 T cells by at least two-fold. 25

3. The method of claim 1, wherein stimulating the proliferation comprises increasing the number of Vy2VS2 T cells by at least ten-fold.

4. The method of claim 1, wherein contacting the cells with the alkylamine agent is 30 performed ex vivo.

5. The method of claim 1, wherein contacting the cells with the alkylamine agent is performed in vivo. WO 00/00158 -37- PCT/US99/14303

6. The method of claim 4, wherein the Vy2VS2 T cell proliferation stimulating amount of the alkylamine agent is from about 0.01 mM to about 100 mM.

7. The method of claim 4, wherein the Vy2V82 T cell proliferation stimulating amount of 5 the alkylamine agent is from about 0.1 mM to about 0.1 mM to about 20 mM.

8. The method of claim 4, wherein the Vy2VS2 T cell proliferation stimulating amount of the alkylamine agent is from about 1 mM to about 10 mM. 10

9. The method of claim 5, wherein the Vy2VS2 T cell proliferation stimulating amount of the alkylamine agent is from about 5 mg/kg to about 100 mg/kg.

10. The method of claim 5, wherein the Vy2V82 T cell proliferation stimulating amount of the alkylamine agent is from about 10 mg/kg to about 50 mg/kg. 15

11. The method of claim 4, wherein the Vy2VS2 T cell proliferation stimulating amount of the alkylamine agent is from about 20 mg/kg to about 30 mg/kg.

12. The method of claim 1, wherein the alkylamine agent is an alkylamine. 20

13. The method of claim 1, wherein the alkylamine agent is an alkylamine precursor.

14. The method of claim 1, wherein R is a straight-chained alkyl group. 25

15. The method of claim 1, wherein R is a branched-chained alkyl group.

16. The method of claim 14, wherein R is saturated.

17. The method of claim 15, wherein R is unsaturated. 30

18. The method of claim 1, wherein the alkylamine is selected from the group consisting of methyl-, ethyl-, n-propyl-, -iso-propyl-, n-butyl, iso-butyl-, sec-butyl-, iso-amyl-, WO 00/00158 - 38 - PCTIUS99/14303 hydroxymethyl -, p-hydroxyethyl-, S-hydroxy propyl-, hydroxy isopropyl-, allyl, crotyl, dimethylallyl, isopentenyl, geranyl, farnesyl, geranylgeranyl, 3-methyl-2-pentenyl, and 3 methyl-2-hexenyl-amine. 5

19. The method of claim 1, wherein R is a straight-chained alkyl group.

20. The method of claim 1, wherein R is a branched-chained alkyl group. 10

21. The method of claim 19, wherein R is saturated.

22. The method of claim 20, wherein R is unsaturated. 15

23. The method of claim 1, wherein RI is a straight- or branched chain alkyl or alkenyl group containing from one to ten carbon atoms. 20

24. The method of claim 1, wherein the RI alkyl group or the RI alkenyl group is selected from the group consisting of propyl, butyl, and amyl.

25. The method of claim 1, wherein RI is a straight- or branched chain alkyl or alkenyl group of a naturally-occurring dicarboxylic acid. 25

26. The method of claim 1, wherein the RI alkyl group or the RI alkenyl group is selected from the group consisting of propyl, butyl, and amyl.

27. The method of claim 1, wherein the monocarboxylic acid and the dicarboxylic acid are 30 selected from the group of naturally-occurring amino acids.

28. The method of claim 1, wherein the dicarboxylic acid is glutamatic acid or aspartic acid.

29. The method of claim 1, wherein the alkylamine precursor is selected from the group 35 consisting of theanine, N 5 -isopropylglutamine, N4-ethyl asparagine, and N 5 -secbutylglutamine.

30. A method for activating a y8 T cell receptor comprising: WO 00/00158 - 39- PCT/US99/14303 contacting the receptor with an alkylamine under conditions to permit alkylamine mediated activation of the receptor, wherein the alkylamine is a compound of formula I: R-NH2 (formula I), 5 or a compound of formula III: R-NR2R3 (formula III) wherein R is a straight- or branched chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive, wherein R2 is a straight- or branched-chain alkyl or alkenyl group containing from one 10 to six carbon atoms, inclusive, that may be the same or different from R, and wherein R3 is a hydrogen or a straight- or branched-chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive, that may be the same or different from R or R2. 15

31. The method of claim 30, wherein contacting the receptor with the alkylamine agent is performed ex vivo.

32. The method of claim 30, wherein contacting the receptor with the alkylamine agent is performed in vivo. 20

33. The method of claim 30, wherein R is a straight-chained alkyl group.

34. The method of claim 30, wherein R is a branched-chained alkyl group. 25

35. The method of claim 33, wherein R is saturated.

36. The method of claim 34, wherein R is unsaturated.

37. The method of claim 30, wherein the alkylamine is selected from the group consisting of 30 ethyl-, n-propyl-, -iso-prolyl-, n-butyl, iso-butyl-, sec-butyl-, and iso-amylamines.

38. A composition comprising: WO 00/00158 -40- PCT/US99/14303 an alkylamine of formula I R-NH2 (formula I), or a compound of formula III: R-NR2R3 (formula III) 5 wherein R is a straight- or branched chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive, wherein R2 is a straight- or branched-chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive, that may be the same or different from R, wherein R3 is a hydrogen or a straight- or branched-chain alkyl or alkenyl group 10 containing from one to six carbon atoms, inclusive, that may be the same or different from R or R2; and. a pharmaceutically acceptable carrier.

39. The composition of claim 38, wherein at least one of R and R2 is a straight-chained 15 alkyl group.

40. The composition of claim 38, wherein at least one of R and R2 is a branched-chained alkyl group. 20

41. The composition of claim 38, wherein at least one of R and R2 is saturated.

42. The composition of claim 38, wherein at least one of R and R2 is unsaturated.

43. The composition of claim 38, wherein the alkylamine is selected from the group 25 consisting of ethyl-, n-propyl-, -iso-prolyl-, n-butyl, iso-butyl-, sec-butyl-, and iso-amylamines.

44. The composition of claim 38, wherein the composition is formulated as an oral formulation. 30

45. The composition of claim 38, wherein the composition is formulated as an oral formulation for administration to a gingival tissue. WO 00/00158 PCT/US99/14303

46. The composition of claim 38, wherein the composition is formulated as a food additive.

47. The composition of claim 38, wherein the composition is formulated for delivery to the female reproductive tract 5

48. The composition of claim 38, wherein the composition is formulated for vaginal delivery.

49. A compound of formula II: 10 0 R1-C-NH-R (formula II), wherein R is a straight- or branched chain alkyl group containing from one to six carbon 15 atoms, and wherein RI is a straight- or branched chain alkyl group containing from one to twenty carbon atoms.

50. The compound of claim 49, wherein R is a straight-chained alkyl group. 20

51. The compound of claim 49, wherein R is a branched-chained alkyl group.

52. The compound of claim 50, wherein R is saturated. 25

53. The compound of claim 51, wherein R is unsaturated.

54. The compound of claim 49, wherein RI is a straight- or branched chain alkyl or alkenyl group containing from one to ten carbon atoms. 30

55. The compound of claim 49, wherein the RI alkyl group or the RI alkenyl group is selected from the group consisting of propyl, butyl, and amyl.

56. The compound of claim 49, wherein RI is a straight- or branched chain alkyl or alkenyl WO 00/00158 -42- PCT/US99/14303 group of a naturally-occurring dicarboxylic acid.

57. The compound of claim 49, wherein the alkylamine precursor is selected from the group consisting of theanine, N 5 - isopropylglutamine, N4-ethyl asparagine, and N -secbutylglutamine. 5

58. The compound of claim 49, wherein the monocarboxylic acid and the dicarboxylic acid are selected from the group of amino acids.

59. The compound of claim 49, wherein the dicarboxylic acid is glutamatic acid or aspartic acid. 10

60. A composition comprising: any of the compounds of claims 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, or 59, and a pharmaceutically acceptable carrier. 15

61. The composition of claim 60, wherein the composition is formulated as an oral formulation.

62. The composition of claim 60, wherein the composition is formulated as an oral formulation for administration to a gingival tissue. 20

63. The composition of claim 60, wherein the composition is formulated as a food additive.

64. The composition of claim 60, wherein the composition is formulated as a food additive for delivery to the female reproductive track. 25

65. The compound of claim 49, wherein the compound is not theanine.

66. The compound of claim 49, wherein the compound is isolated from contaminants that render it unsuitable for therapeutic applications. 30

67. A method for stimulating the activation of Vy2V82 T cells comprising: contacting the cells with a Vy2VS2 T cell activation stimulating amount of an WO 00/00158 - 43- PCT/US99/14303 alkylamine agent selected from the group consisting of an alkylamine of formula I: R-NH2 (formula I), an alkylamine of formula III: R-NR2R3 (formula III) 5 and an alkylamine precursor of formula II, 0 RI -C-NH-R (formula II), 10 wherein R is a straight- or branched chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive, wherein RI is a straight- or branched chain alkyl or alkenyl group containing from one to twenty carbon atoms, inclusive, wherein R2 is a straight- or branched-chain alkyl or alkenyl group containing from one 15 to six carbon atoms, inclusive, that may be the same or different from R, and wherein R3 is hydrogen or a straight- or branched-chain alkyl or alkenyl group containing from one to six carbon atoms, inclusive, that may be the same or different from R or R2. 20

68. The method of claim 67, wherein stimulating the activation comprises stimulating cytokine production by Vy2V62 T cells.

69. The method of claim 68, wherein the cytokines are selected from the group consisting of interferon-gamma (IFN-gamma), interleukin-2 (IL-2), tumor necrosis factor-beta (TNF-beta, 25 Lymphotoxin), interleukin-4 (IL-4), IL-5, IL-10, and TNF-a.

70. The method of claim 67, wherein stimulating the activation comprises stimulating proliferation of Vy2V82 T cells. 30

71. The method of claim 67, wherein stimulating the activation comprises stimulating cytotoxic activity by Vy2V62 T cells.

72. The method of claim 67, wherein stimulating the activation comprises stimulating blocking the activity of Vy2VS2 T cells. WO 00/00158 PCT/US99/14303

73. The method of claim 67, wherein stimulating the activation comprises stimulating the Vy2VS2 T cells to apoptose and die.

74. The method of claim 67, wherein contacting the cells with the alkylamine agent is 5 performed ex vivo.

75. The method of claim 67, wherein contacting the cells with the alkylamine agent is performed in vivo. 10

76. The method of claim 74, wherein the Vy2VS2 T cell activation stimulating amount of the alkylamine agent is from about 0.01 mM to about 100 mM.

77. The method of claim 74, wherein the Vy2V62 T cell activation stimulating amount of the alkylamine agent is from about 0.1 mM to about 0.1 mM to about 20 mM. 15

78. The method of claim 74, wherein the Vy2V82 T cell activation stimulating amount of the alkylamine agent is from about 1 mM to about 10 mM.

79. The method of claim 75, wherein the Vy2VS2 T cell activation stimulating amount of 20 the alkylamine agent is from about 5 mg/kg to about 100 mg/kg.

80. The method of claim 75, wherein the Vy2V82 T cell activation stimulating amount of the alkylamine agent is from about 10 mg/kg to about 50 mg/kg. 25

81. The method of claim 75, wherein the Vy2VS2 T cell proliferation stimulating amount of the alkylamine agent is from about 20 mg/kg to about 30 mg/kg.

82. The method of claim 67, wherein the alkylamine agent is an alkylamine. 30

83. The method of claim 67, wherein the alkylamine agent is an alkylamine precursor.

84. The method of claim 67, wherein R is a straight-chained alkyl group. WO 00/00158 - 45- PCT/US99/14303

85. The method of claim 67, wherein R is a branched-chained alkyl group.

86. The method of claim 84, wherein R is saturated. 5

87. The method of claim 85, wherein R is unsaturated.

88. The method of claim 67, wherein the alkylamine is selected from the group consisting of methyl-, ethyl-, n-propyl-, -iso-propyl-, n-butyl, iso-butyl-, sec-butyl-, iso-amyl-, hydroxymethyl -, p-hydroxyethyl-, 6-hydroxy propyl-, hydroxy isopropyl-, allyl, crotyl, 10 dimethylallyl, isopentenyl, geranyl, farnesyl, geranylgeranyl, 3-methyl-2-pentenyl, and 3 methyl-2-hexenyl-amine.

89. The method of claim 67, wherein R is a straight-chained alkyl group. 15

90. The method of claim 67, wherein R is a branched-chained alkyl group.

91. The method of claim 89, wherein R is saturated.

92. The method of claim 90, wherein R is unsaturated. 20

93. The method of claim 67, wherein RI is a straight- or branched chain alkyl or alkenyl group containing from one to ten carbon atoms.

94. The method of claim 67, wherein the RI alkyl group or the RI alkenyl group is selected 25 from the group consisting of propyl, butyl, and amyl.

95. The method of claim 67, wherein RI is a straight- or branched chain alkyl or alkenyl group of a naturally-occurring dicarboxylic acid. 30

96. The method of claim 67, wherein the RI alkyl group or the RI alkenyl group is selected from the group consisting of propyl, butyl, and amyl. WO 00/00158 -46- PCT/US99/14303

97. The method of claim 67, wherein the monocarboxylic acid and the dicarboxylic acid are selected from the group of naturally-occurring amino acids.

98. The method of claim 67, wherein the dicarboxylic acid is glutamatic acid or aspartic 5 acid.

99. The method of claim 67, wherein the alkylamine precursor is selected from the group consisting of theanine, N - isopropylglutamine, N4-ethyl asparagine, and N 5 -secbutylglutamine. 10